EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 8-9 (Août-Septembre 2004) Med Sci (Paris), 20 8-9 (2004) 788-792 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 8-9, Août-Septembre 2004
Page(s) 788 - 792
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004208-9788
Published online 15 August 2004
  1. Blumberg-Mokri M. Les inventions biotechnologiques. Biofutur 2002; 218 : 42–3. [Google Scholar]
  2. Sobol H, Bignon YJ, Bonaiti C, et al. Four years analysis of cancer genetic clinics activity in France form 1994 to 1997 : a survey on 801 patients. Dis Markers 1999; 15 : 1–15. [Google Scholar]
  3. Miki Y, Swensen J, Shattuck-Eiders D, et al. A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science 1994; 266 : 66–71. [Google Scholar]
  4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378 : 789–92. [Google Scholar]
  5. Expertise collective Inserm. Risques héréditaires de cancer du sein et de l’ovaire : quelle prise en charge ? Paris : Inserm, 1998 : 636 p. [Google Scholar]
  6. Eisinger F, Alby N, Bremond A, et al. Recommendations for medical management of hereditary breast and ovarian cancer : the French National Ad Hoc Committee. Ann Oncol 1998; 9 : 939–50. [Google Scholar]
  7. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. J Clin Oncol 1996; 14 : 1730–6. [Google Scholar]
  8. Butler D, Goodman S. French researchers take a stand against cancer gene patent. Nature 2001; 413 : 95–6. [Google Scholar]
  9. Benowitz S. French challenge to BRCA1 patent underlies European discontent. J Natl Cancer Inst 2002; 94 : 80–1. [Google Scholar]
  10. Wadman M. Testing time for gene patent as Europe rebels. Nature 2001; 413 : 443. [Google Scholar]
  11. Sevilla C, Julian-Reynier C, Eisinger F, et al. The impact of gene patents on the cost-effective delivery of care : The case of BRCA1 genetic testing. Int J Technol Assess Health Care 2003; 19 : 287–300. [Google Scholar]
  12. Sevilla C, Moatti JP, Julian-Reynier C, et al. Testing for BRCA1 mutations : A cost-effectiveness analysis. Eur J Hum Genet 2002; 10 : 599–606. [Google Scholar]
  13. Brower V. Testing, testing… testing ? Nat Med 1997; 3 : 131–2. [Google Scholar]
  14. Kaufert PA. Health policy and the new genetics. Soc Sci Med 2000; 51 : 821–9. [Google Scholar]
  15. Reynolds T. NCI-Myriad agreement offers BRCA testing at reduced cost. J Natl Cancer Inst 2000; 92 : 596. [Google Scholar]
  16. Hollon T. NIH researchers receive cut-price BRCA test. Nat Med 2000; 6 : 610. [Google Scholar]
  17. Cassier M, Gaudillière JP. Recherche, médecine et marché : la génétique du cancer du sein. Sci Soc Santé 2000; 18 : 29–49. [Google Scholar]
  18. Gold ER, Caulfield TA. The moral tollbooth : A method that makes use of the patent system to address ethical concerns in biotechnology. Lancet 2002; 359 : 2268–70. [Google Scholar]
  19. Zick CD, Smith KR, Mayer RN, Botkin JR. Genetic testing, adverse selection, and the demand for life insurance. Am J Med Genet 2000;93 : 29–39. [Google Scholar]
  20. Hoel M, Iversen T. Genetic testing when there is a mix of compulsory and voluntary health insurance. J Health Econ 2002; 21 : 253–70. [Google Scholar]
  21. Strohmenger R, Wambach A. Adverse selection and categorical discrimination in the health insurance markets: the effects of genetic tests. J Health Econ 2000; 19 : 197–218. [Google Scholar]
  22. C;ller H. Genetic testing for cancer predisposition-an ongoing debate. Lancet Oncol 2000; 1 : 118–9. [Google Scholar]
  23. Matloff ET, Shappell H, Brierley K, et al. What would you do ? Specialists’ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000; 18 : 2484–92. [Google Scholar]
  24. Peterson EA, Milliron KJ, Lewis KE, et al. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarker Prev 2002; 11 : 79–87. [Google Scholar]
  25. Julian-Reynier C, Sobol H, Sevilla C, et al. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. Psycho- Oncology 2000; 9 : 504–10. [Google Scholar]
  26. Julian-Reynier C, Eisinger F, Chabal F, et al. Disclosure to the family of breast/ovarian cancer genetic test results : patient’s willingness and associated factors. Am J Med Genet 2000; 94 : 13–8. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.